The UK’s health data landscape is undergoing a seismic transformation, with ambitions to move from fragmented silos to a connected, secure ecosystem for research and innovation. Historically, health data in Britain was scattered: General Practitioner (GP) records, hospital episodes, and social care data existed in separate systems, making comprehensive real world research challenging. Today, driven by a national strategy and significant investment, the Department of Health and Social Care (DHSC) and National Health Service (NHS) are linking these domains. Secure Data Environments (SDEs) have been established across regions to safely unite primary, secondary, laboratory, and social care data.
It is worth being clear what “secure” means in practice. An SDE allows accredited teams to analyse sensitive data within a tightly controlled setting, preventing data export or removal. Strict access controls, careful handling of identifiers, and thorough result checks enable secure analysis, including privacy-preserving record linkage (PPRL), while upholding public trust. This approach requires not just technical measures but also robust governance and privacy frameworks. At scale, the focus is on ensuring health data can be linked lawfully, proportionately, and with public legitimacy. SDEs combine data platform functions with privacy protections like pseudonymisation to enable analysis and minimise identifiability risks.
In parallel, the forthcoming Health Data Research Service (HDRS) will serve as a one-stop access point or “single front door”, with the long-term goal of providing a national data view under harmonised governance, driving further standardisation of processes across the country. HDRS was a key recommendation of the Sudlow Review with £600 million investment from the Government and the Wellcome Trust announced last April. This represents one of the largest national endeavours in unlocking health data for the purpose of research the UK has ever seen. But what does all this mean for life sciences companies?
The evolving UK health data landscape offers life sciences companies unprecedented opportunities. With access to richly linked, longitudinal datasets, researchers can track the entire patient journey through the healthcare system. Privacy-preserving record linkage (PPRL) is a key enabler here. It allows records from different parts of the system to be connected so researchers can understand pathways and outcomes, without making direct identifiers part of the routine research workflow. For life sciences teams, that means better longitudinal insight with fewer barriers, because the linkage approach aligns more naturally with the safeguards that data custodians, regulators, and the public increasingly expect.
This comprehensive visibility enables studies across care settings, helping to identify ways to optimise treatment pathways and uncover inequities in patient access. Furthermore, by combining data to create larger cohorts, researchers are empowered to pursue investigations in rare diseases, which are challenging due to limited patient numbers. These advancements foster closer alignment with the real-world challenges faced by the NHS and encourage partnerships that focus on designing impactful interventions, moving research from isolated environments to genuine, practical outcomes.
Several NHS regions are actively seeking collaboration on research projects, with SDE leads welcoming input from life science companies about data priorities and use cases. This creates opportunities for strategic partnerships, enabling industry stakeholders to engage with SDEs and help shape the development of data assets to better suit research needs. Collaborative approaches are emerging, wherein companies and NHS data custodians work together to build disease registries or improve data quality in areas of shared interest.
As the data landscape becomes more integrated, life sciences organisations are equipped to leverage UK datasets more effectively, ranging from streamlined clinical trial recruitment to demonstrating the value of therapies, tracking outcomes, and analysing healthcare resource utilisation at scale to showcase real world impact.
The overarching vision is to make Real World Evidence (RWE) generation faster and more robust. This shift will facilitate deeper insights into the natural history of diseases, effectiveness of treatments, and the characteristics of patient sub-populations. By capitalising on these opportunities, life sciences companies are poised to make substantial contributions to research and patient care in the UK.
Life sciences companies face significant hurdles as they navigate the evolving health data ecosystem in the UK. Foremost among these is the complexity of information governance. Each regional SDE operates with its own processes and approval requirements. While all regions adhere to overarching NHS guidelines, there are notable differences in practice. Certain areas have developed advanced, user-friendly systems, whereas others are still in the process of building their capabilities. This inconsistency across regions can inadvertently introduce selection bias and create confusion for organisations seeking to access these data platforms.
The introduction of the HDRS aims to address these challenges by providing a unified portal, but during the transitional period from 2025 to 2027, companies will need to invest significant time in understanding and adapting to the new rules of engagement. Navigating information governance processes may feel more burdensome compared to previous methods involving readily licensed databases. However, these frameworks play a crucial role ensuring there is clarity about who is responsible for what, why data is being used, how privacy risks are assessed and managed and maintaining public trust. This is particularly important as the UK moves from isolated datasets to richer, linked, longitudinal insight, the privacy dimension becomes more important, not less. Even when direct identifiers are not part of the research workflow, combining multiple datasets can increase the chance that individuals are indirectly recognisable through rare combinations of characteristics or very small numbers in particular groups. This is one reason SDE approaches place such emphasis on privacy-preserving record linkage (PPRL), careful access controls, maximising the safe use of pseudonymisation techniques, and careful quality checking of results before outputs are released. Done well, these safeguards protect public confidence while still enabling high-value longitudinal research.
Life sciences teams are encouraged to perceive robust governance not as a bureaucratic barrier, but as a fundamental enabler of data access and provide clear expectations on study design, analysis and publication requirements.
Another considerable challenge is the variability and quality of data across regions. Not all NHS data sets are clean or complete once they are linked, with discrepancies in coding and data capture existing between different hospitals and GP systems. This can lead to initial datasets that are inconsistent or incomplete. Curated datasets continue to offer greater reliability compared to raw, newly linked data. Consequently, companies must dedicate effort to cleaning and validating data for their specific research needs or collaborate with partners who possess these expertise. Effective utilisation of these new datasets demands strong skills in data wrangling and analysis, including the capability to distinguish genuine insights from background noise. For a time, companies may need to conduct projects on a region-by-region basis, subsequently integrating findings, as a fully unified and consistently high-quality dataset across the UK remains a work in progress.
A more nuanced challenge emerges with the gradual reduction of proprietary data exclusivity. As the UK works to democratise access to health data, making it available to all accredited researchers via secure platforms, the competitive landscape is changing. The advantage is transitioning from the possession of unique data to the ability to derive meaningful insights from commonly available datasets. In this new environment, data themselves are increasingly commoditised, and the true value lies in extracting actionable insights. This shift necessitates that life sciences companies build new capabilities, either by investing in internal data science teams or by forming partnerships with organisations like IQVIA who are deeply familiar with NHS data, to maintain their competitive edge.
To succeed in the evolving UK health data landscape, life sciences companies must focus on developing and acquiring the necessary skills within their organisations. Alongside scientific and analytical capability, organisations increasingly need governance and privacy capability that is practical rather than purely legal. That includes understanding how privacy preserving technology enables data to be maximised safely, including PPRL in an SDE context, how to design studies that minimise identifiability risk, and how to work confidently with the governance expectations that sit behind approvals and output controls. For life sciences teams, these skills are becoming part of the “speed to insight” equation, because they reduce friction in access, help avoid rework, and support more repeatable research at scale. Companies should invest in upskilling their existing teams, ensuring they are proficient in the latest methodologies and technologies for handling and interpreting health data.
Given that this explosion in health data access is not limited to the UK but is on a multinational scale, life sciences companies play a role in promoting better coordination and consistency in data standards and processes at a global level. One example is the European Health Data Space (EHDS)1, an EU initiative designed to establish a unified system for the secure and ethical reuse of electronic health data throughout Europe, similar to the UK HDRS. Life sciences have an important voice in aligning these initiatives and ensuring best practices go across borders. This ultimately enables more efficient and effective multi-country RWE projects possible supporting international researchers across the board.
Given the breadth of skills and the range of stakeholders involved in this process, it is also important to identify and collaborate with external partners where needed. Organisations like IQVIA can provide end-to-end services or fill specific gaps in expertise, supporting the full spectrum of data analytics and governance requirements.
Companies that experiment now will gain a learning advantage, for example, starting pilot projects with one or two SDEs to get familiar with the process. Early engagement builds relationships, being curious and understand SDE operating models, access control mechanisms and approval processes will help ensure scientific teams can design studies that are both robust and operationally feasible and position your company as a trusted collaborator. Staying abreast of HDRS developments and participating in user consultations or beta programs will also be important.
The scale of data available invites a scale of collaboration to match. Deeper partnerships with NHS bodies and academic partners should be considered to create disease-focused data hubs or registries. Demonstrating a commitment to improving healthcare, not just extracting data, builds trust and often results in better data.
Map out evidence plans early in the development and launch cycle. Build flexibility into your plans, as regulatory, commercial, and external factors can change. Adopt a more agile approach to evidence generation, thinking in terms of a rolling programme of inquiries that can adjust as needed.
Finally, public and stakeholder trust is paramount. The success of the UK data initiative hinges on demonstrating tangible benefits to patients and society. Life sciences companies share in the responsibility to use data transparently and for the benefit of patients. By visibly contributing insights that improve healthcare, companies strengthen the virtuous circle of trust.
The UK’s evolving health data landscape offers a new frontier for the life sciences industry. Companies that adapt by building data-savvy teams underpinned by information governance expertise, engaging early with NHS data platforms, forging collaborative relationships, and integrating RWE into their core strategy will be poised to lead in this new era.
The direction of travel is clear: more connectivity, more data, and more opportunity to improve patient outcomes and demonstrate value.
1. IQVIA white paper on European Health Data Space (EHDS): A Comprehensive Guide to Data Reuse - https://www.iqvia.com/library/white-papers/european-health-data-space-ehds
IQVIA is actively partnering with NHS organisations and supporting life sciences clients in navigating the UK’s health data revolution. This includes helping teams design evidence programmes that are operationally feasible within SDE models, with privacy and linkage approaches, including PPRL, embedded from the outset so that access, analysis, and outputs can move at pace while maintaining public and stakeholder confidence. Connect with us to learn how we can help you maximise the value of the evolving UK health data ecosystem.
IQVIA Real World Solutions is the proven partner life science companies trust to take on their complex evidence challenges. We enable our customers to generate and disseminate real world evidence to answer crucial questions and meet the needs of their stakeholders.
